Terms: = Endocrine gland cancer AND MALT1, ENSG00000172175, 10892 AND Treatment
3 results:
1. CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.
Salgado-Albarrán M; Späth J; González-Barrios R; Baumbach J; Soto-Reyes E
NPJ Syst Biol Appl; 2022 Feb; 8(1):5. PubMed ID: 35132075
[TBL] [Abstract] [Full Text] [Related]
2. Biperiden and mepazine effectively inhibit malt1 activity and tumor growth in pancreatic cancer.
Konczalla L; Perez DR; Wenzel N; Wolters-Eisfeld G; Klemp C; Lüddeke J; Wolski A; Landschulze D; Meier C; Buchholz A; Yao D; Hofmann BT; Graß JK; Spriestersbach SL; Grupp K; Schumacher U; Betzel C; Kapis S; Nuguid T; Steinberg P; Püschel K; Sauter G; Bockhorn M; Uzunoglu FG; Izbicki JR; Güngör C; El Gammal AT
Int J Cancer; 2020 Mar; 146(6):1618-1630. PubMed ID: 31291468
[TBL] [Abstract] [Full Text] [Related]
3. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Mahanivong C; Chen HM; Yee SW; Pan ZK; Dong Z; Huang S
Oncogene; 2008 Feb; 27(9):1273-80. PubMed ID: 17724468
[TBL] [Abstract] [Full Text] [Related]
